Navellier & Associates Inc. Has $283,000 Stake in Merck & Co., Inc. $MRK

Navellier & Associates Inc. decreased its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 68.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,686 shares of the company’s stock after selling 5,707 shares during the quarter. Navellier & Associates Inc.’s holdings in Merck & Co., Inc. were worth $283,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. Vanguard Group Inc. grew its position in shares of Merck & Co., Inc. by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 254,322,763 shares of the company’s stock worth $26,770,014,000 after buying an additional 2,185,853 shares during the period. DLD Asset Management LP lifted its stake in Merck & Co., Inc. by 30.1% in the third quarter. DLD Asset Management LP now owns 47,500,000 shares of the company’s stock valued at $3,986,675,000 after buying an additional 11,000,000 shares in the last quarter. Legal & General Group Plc lifted its stake in Merck & Co., Inc. by 5.9% in the third quarter. Legal & General Group Plc now owns 20,659,157 shares of the company’s stock valued at $1,733,923,000 after buying an additional 1,156,112 shares in the last quarter. Invesco Ltd. lifted its stake in Merck & Co., Inc. by 16.6% in the third quarter. Invesco Ltd. now owns 19,844,936 shares of the company’s stock valued at $1,665,585,000 after buying an additional 2,821,766 shares in the last quarter. Finally, Ameriprise Financial Inc. lifted its stake in Merck & Co., Inc. by 20.7% in the third quarter. Ameriprise Financial Inc. now owns 15,933,909 shares of the company’s stock valued at $1,336,877,000 after buying an additional 2,735,459 shares in the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck published a Science paper describing a scalable, enzyme-driven synthesis for its investigational oral PCSK9 inhibitor enlicitide decanoate — a notable R&D milestone that supports the commercial potential of a new oral lipid-lowering modality. Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate
• Positive Sentiment: Merck’s BioReliance unit inked a five‑year deal to be the sole testing provider for Genetix Biotherapeutics’ FDA‑approved gene therapies — adds recurring, commercial‑stage service revenue and reinforces Merck’s role in cell & gene therapy commercialization. Merck Becomes Sole Testing Provider for Genetix Biotherapeutics’ FDA-Approved Gene Therapies
• Positive Sentiment: Merck completed the Terns acquisition to expand its chronic myeloid leukemia (CML) pipeline; the deal and FDA breakthrough designation for a TERN asset strengthen oncology pipeline optionality. MSD concludes Terns acquisition to expand CML pipeline
• Positive Sentiment: Analysts and brokers showed support after Merck’s Q1 beat — one analyst nudged the price target higher and BMO reiterated a buy — giving near‑term fundamental backing to the stock. Analyst Raises Merck (MRK) Price Target by $1 After Beating Q1 Estimates BMO Capital Remains a Buy on Merck & Company (MRK)
• Neutral Sentiment: Merck Animal Health selected Salesforce’s Agentforce Life Sciences for omnichannel engagement — a strategic IT/customer‑engagement win but with modest near‑term financial impact versus drug/cell‑therapy drivers. Salesforce AI Win With Merck Highlights Real World Platform Adoption
• Neutral Sentiment: Citigroup initiated coverage with a “neutral” rating and a $125 price target — supportive of upside but not a strong buy signal; highlights mixed analyst views on valuation vs. growth. Citigroup Initiates Coverage
• Negative Sentiment: Sector competitors posted robust oncology and diabetes results (J&J oncology growth; Eli Lilly’s blockbuster Mounjaro sales), underscoring competitive pressure in key therapeutic areas and possibly contributing to profit‑taking and relative valuation compression for Merck. Sector Competitive Moves Darzalex, Erleada & New Drugs Keep J&J’s Oncology Engine Charged in Q1 Eli Lilly Now Has the World’s Best-Selling Drug — But Does That Make the Stock a No-Brainer Buy?

Insider Activity at Merck & Co., Inc.

In related news, CMO Chirfi Guindo sold 10,000 shares of Merck & Co., Inc. stock in a transaction on Monday, February 9th. The shares were sold at an average price of $118.41, for a total value of $1,184,100.00. Following the completion of the sale, the chief marketing officer owned 70,615 shares of the company’s stock, valued at approximately $8,361,522.15. This trade represents a 12.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Jennifer Zachary sold 121,573 shares of Merck & Co., Inc. stock in a transaction on Monday, February 9th. The stock was sold at an average price of $119.15, for a total value of $14,485,422.95. Following the sale, the executive vice president owned 68,916 shares in the company, valued at $8,211,341.40. The trade was a 63.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 0.17% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on MRK. Zacks Research raised shares of Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 17th. Wall Street Zen raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Saturday, March 28th. JPMorgan Chase & Co. lifted their price target on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the company an “overweight” rating in a research note on Monday, April 6th. TD Cowen lifted their price target on shares of Merck & Co., Inc. from $100.00 to $120.00 and gave the company a “hold” rating in a research note on Tuesday, January 20th. Finally, Barclays began coverage on shares of Merck & Co., Inc. in a research note on Friday, February 20th. They issued an “overweight” rating and a $140.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have given a Hold rating to the company. According to MarketBeat, Merck & Co., Inc. has an average rating of “Moderate Buy” and an average price target of $128.18.

Merck & Co., Inc. Trading Down 1.2%

Shares of Merck & Co., Inc. stock opened at $112.22 on Friday. The company has a market capitalization of $277.17 billion, a price-to-earnings ratio of 31.61, a PEG ratio of 2.56 and a beta of 0.18. The company has a quick ratio of 1.30, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. Merck & Co., Inc. has a 12-month low of $73.31 and a 12-month high of $125.14. The firm’s 50-day moving average price is $117.07 and its two-hundred day moving average price is $108.31.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. The firm had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same period in the prior year, the company posted $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, analysts forecast that Merck & Co., Inc. will post 5.16 earnings per share for the current fiscal year.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.